Effects of fluctuating oxygenation on tirapazamine efficacy: Theoretical predictions

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 2, 2007, Pages 581-586

  Cárdenas Navia, L Isabel ^a   Secomb, Timothy W ^b   Dewhirst, Mark W ^a,c  

^a Duke University   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fluctuating hypoxia; Hypoxic cytotoxins; Tirapazamine

Indexed keywords

COMPUTER SIMULATION; NATURAL FREQUENCIES; OXYGEN; OXYGENATORS; PATIENT TREATMENT;

FLUCTUATING HYPOXIA; HYPOXIC CYTOTOXINS; SENSITIVE AGENTS; TIRAPAZAMINES;

AMINES;

CYTOTOXIN; TIRAPAZAMINE;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; EXPERIMENTAL STUDY; FREQUENCY ANALYSIS; HYPOXIA; HYPOXIC CELL; IN VITRO STUDY; OXYGEN TISSUE LEVEL; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; SIMULATION; STEADY STATE; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL SURVIVAL; MODELS, BIOLOGICAL; OXYGEN; PARTIAL PRESSURE; TIME FACTORS; TRIAZINES;

EID: 33846208294     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.10.002     Document Type: Article

References (39)

1. Zeman E.M., Hirst V.K., Lemmon M.J., et al. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 12 (1988) 209-218
2. Zeman E.M., Brown J.M., Lemmon M.J., et al. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12 (1986) 1239-1242
3. Hicks K.O., Siim B.G., Pruijn F.B., et al. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: Implications for extravascular transport and activity in tumors. Radiat Res 161 (2004) 656-666
4. Kyle A.H., and Minchinton A.I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol 43 (1999) 213-220
5. Hicks K.O., Pruijn F.B., Sturman J.R., et al. Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 63 (2003) 5970-5977
6. Hicks K.O., Fleming Y., Siim B.G., et al. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int J Radiat Oncol Biol Phys 42 (1998) 641-649
7. Durand R.E., and Olive P.L. Evaluation of bioreductive drugs in multicell spheroids. Int J Radiat Oncol Biol Phys 22 (1992) 689-692
8. Durand R.E., and Olive P.L. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Investig 5 (1997) 213-219
9. Minchinton A.I., and Brown J.M. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing. Br J Cancer 66 (1992) 1053-1058
10. Chaplin D.J., and Hill S.A. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 71 (1995) 1210-1213
11. Chaplin D.J., Olive P.L., and Durand R.E. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res 47 (1987) 597-601
12. Brurberg K.G., Skogmo H.K., Graff B.A., et al. Fluctuations in pO(2) in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother Oncol 77 (2005) 220-226
13. Brurberg K.G., Graff B.A., and Rofstad E.K. Temporal heterogeneity in oxygen tension in human melanoma xenografts. Br J Cancer 89 (2003) 350-356
14. Brurberg K.G., Graff B.A., Olsen D.R., et al. Tumor-line specific pO(2) fluctuations in human melanoma xenografts. Int J Radiat Oncol Biol Phys 58 (2004) 403-409
15. Brown J. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 52 (1979) 650-656
16. Dewhirst M.W., Braun R.D., and Lanzen J.L. Temporal changes in PO2 of R3230AC tumors in Fischer-344 rats. Int J Radiat Oncol Biol Phys 42 (1998) 723-726
17. Cardenas-Navia L.I., Braun R., Lewis K., et al. Comparison of fluctuations of oxygen tension in FSA, 9L, and R3230AC tumors in rats. Adv Exp Med Biol 510 (2003) 7-12
18. Durand R.E., and LePard N.E. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol 34 (1995) 317-323
19. Ljungkvist A.S., Bussink J., Rijken P.F., et al. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 48 (2000) 1529-1538
20. Minchinton A.I., Durand R.E., and Chaplin D.J. Intermittent blood flow in the KHT sarcoma-flow cytometry studies using Hoechst 33342. Br J Cancer 62 (1990) 195-200
21. Minchinton A.I., and Fryer K.H. Fluctuations in the oxygenation of experimental tumours. Adv Exp Med Biol 388 (1996) 353-356
22. Trotter M.J., Chaplin D.J., Durand R.E., et al. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 16 (1989) 931-934
23. Baudelet C., and Gallez B. Cluster analysis of BOLD fMRI time series in tumors to study the heterogeneity of hemodynamic response to treatment. Magn Reson Med 49 (2003) 985-990
24. Bennewith K.L., Raleigh J.A., and Durand R.E. Orally administered pimonidazole to label hypoxic tumor cells. Cancer Res 62 (2002) 6827-6830
25. Braun R.D., Lanzen J.L., and Dewhirst M.W. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. Am J Physiol 277 (1999) H551-H568
26. Graham M.A., Senan S., Robin Jr. H., et al. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 40 (1997) 1-10
27. Wouters B.G., and Brown J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 147 (1997) 541-550
28. Minchinton A.I., Tonn D.A., Sutherland D.P., et al. Carbogen breathing after irradiation enhances the effectiveness of tirapazamine in SiHa tumors but not SCCVII tumors in mice. Radiat Res 158 (2002) 94-100
29. Masunaga S., Nagasawa H., Uto Y., et al. The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations. Int J Hypertherm 21 (2005) 305-318
30. Maxim P.G., Carson J.J., Ning S., et al. Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors. Radiat Res 162 (2004) 185-193
31. Huxham L.A., Kyle A.H., Baker J.H., et al. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother Oncol 78 (2006) 138-145
32. Le Q.T., McCoy J., Williamson S., et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res 10 (2004) 5418-5424
33. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
34. Aquino V.M., Weitman S.D., Winick N.J., et al. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: A pediatric oncology group study. J Clin Oncol 22 (2004) 1413-1419
35. Rischin D., Peters L., Hicks R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 535-542
36. Covens A., Blessing J., Bender D., et al. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecol Oncol Group study. Gynecol Oncol 100 (2006) 586-590
37. Teicher B.A., Lazo J.S., and Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41 (1981) 73-81
38. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev 13 (1994) 139-168
39. Kimura H., Braun R.D., Ong E.T., et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56 (1996) 5522-5528